Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Femara (letrozole) Tablets, 2.5 mg, Novartis NDA 20-726/S8 1/17/03 1/23/03 1/23/03 Femara (letrozole) Tablets, Novartis NDA 20-726/S-006 1/10/01 1/16/01 1/16/01 7/12/01 Femara (letrozole) Tablets, Novartis NDA 20-726/S-005 2/26/03 3/10/03 3/11/03 Femara Indications: First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. | Femara (Letrozole) Tablets, Novartis Pharma, New or Modified Indication | Femara (Letrozole) Tablets, Novartis Pharma, New or Modified Indication | Femara (letrozole) Tablets, Novartis Pharma, Labeling Revision | Femara (letrozole) Tablets, Novartis Pharma, Labeling Revision | Letrozole Tablets, Mylan Pharma, Tentative Approval | Femara (letrozole) Tablets, Novartis Pharmaceuticals Corp., Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2008 Betterchem.com